GNDS, all follow up | −4.09 (−5.25 to −2.94) | −2.93 (−4.09 to −1.77) | −1.16 (−2.75 to 0.43) |
GNDS, treatment compliant | −4.56 (−5.75 to −3.37) | −3.19 (−4.36 to −2.02) | −1.37 (−3.00 to 0.27) |
Kurtzke, all follow up | −0.01 (−0.17 to 0.15) | 0.16 (0.00 to 0.32) | −0.17 (−0.39 to 0.05) |
Kurtzke, treatment compliant | −0.10 (−0.27 to 0.06) | 0.13 (−0.03 to 0.30) | −0.24 (−0.46 to −0.01)a |
Beck, all follow up | −4.87 (−6.48 to −3.27) | −3.44 (−5.04 to −1.85) | −1.43 (−3.62 to 0.76) |
Beck, treatment compliant | −6.24 (−7.57 to −4.90) | −4.71 (−6.01 to −3.41) | −1.53 (−3.35 to 0.29) |
MS symptoms, all follow up | −7.82 (−10.82 to −4.82) | −4.52 (−7.49 to −1.56) | −3.30 (−7.41 to 0.81) |
MS symptoms, treatment compliant | −9.64 (−12.77 to −6.51) | −5.19 (−8.16 to −2.21) | −4.45 (−8.71 to −0.19)b |
MS ADL, all follow up | 1.59 (−0.41 to 3.59) | 1.58 (−0.43 to 3.58) | 0.01 (−2.72 to 2.75) |
MS ADL, treatment compliant | 1.86 (−0.36 to 4.09) | 2.18 (0.00 to 4.35) | −0.31 (−3.35 to 2.73) |
Fatigue, all follow up | −2.14 (−2.81 to −1.47) | −1.16 (−1.83 to −0.5) | −0.98 (−1.89 to −0.06)c |
Fatigue, treatment compliant | −2.52 (−3.21 to −1.83) | −1.56 (−2.22 to −0.9) | −0.96 (−1.89 to −0.03)d |